Sign in

IONS on Nasdaq

IONIS PHARMACEUTICALS INC

IONIS PHARMACEUTICALS INC is an American pharmaceutical preparations company, incorporated in California.1 It is headquartered in Carlsbad, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with MADRIGAL PHARMACEUTICALS, INC., ANI PHARMACEUTICALS INC or Harmony Biosciences Holdings, Inc., or pick any stock.

  • TickerIONS on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCarlsbad, California1
  • Incorporated inCA2
  • Business address2855 Gazelle Court, Carlsbad, Ca 920102
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-40.4%Operating margin4
-40.4%Net margin4
33.8%Revenue growth, 20254
-78.0%Return on equity4
2.72×Debt to equity4
-$320.0MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Royalty brought in 37% of the revenue IONIS PHARMACEUTICALS INC broke down this way in fiscal 2025.

  1. Royalty$285.5M437%up 11% from 2024
  2. Spinraza Royalties$212.3M428%down 2% from 2024
  3. Tryngolza Sales$107.5M414%
  4. Wainus Royalties$49.1M46%up 143% from 2024
  5. Wainua Joint Development Revenue$42.1M46%down 47% from 2024
  6. Other Commercial$35.0M45%down 2% from 2024
  7. Other Royalties$24.2M43%up 15% from 2024
  8. Dawnzera Sales$7.8M41%
Products and services by year
Products and services202320242025
Royalty$272.8M$257.3M$285.5M
Spinraza Royalties$240.4M$216.1M$212.3M
Tryngolza Sales$0$0$107.5M
Wainus Royalties$0$20.2M$49.1M
Wainua Joint Development Revenue$126.4M$79.4M$42.1M
Other Commercial$35.8M$35.8M$35.0M
Other Royalties$32.4M$21.0M$24.2M
Dawnzera Sales$0$0$7.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue1¢$15.9M
  • Research and development68¢$915.6M
  • Selling, general and admin29¢$393.9M
  • Interest1¢$17.3M
  • Income tax0¢$1.8M

Out of $943.7M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$943.7M in 2025−16% since 2019
0$500.0M$1.0B$1.5B2019: $1.1B$1.1B20192020: $729.3M$729.3M2020−35%2021: $810.5M$810.5M2021+11%2022: $587.4M$587.4M2022−28%2023: $787.6M$787.6M2023+34%2024: $705.1M$705.1M2024−10%2025: $943.7M$943.7M2025+34%
Operating income56784-$381.7M in 2025
-$500.0M-$250.0M0$250.0M$500.0M2019: $365.9M$365.9M20192020: -$172.1M-$172.1M20202021: -$30.2M-$30.2M2021−82%2022: -$410.2M-$410.2M2022+1259%2023: -$353.7M-$353.7M2023−14%2024: -$475.1M-$475.1M2024+34%2025: -$381.7M-$381.7M2025−20%
Net income56784-$381.4M in 2025
-$600.0M-$400.0M-$200.0M0$200.0M$400.0M2019: $278.1M$278.1M20192020: -$444.3M-$444.3M20202021: -$28.6M-$28.6M2021−94%2022: -$269.7M-$269.7M2022+843%2023: -$366.3M-$366.3M2023+36%2024: -$453.9M-$453.9M2024+24%2025: -$381.4M-$381.4M2025−16%

Every line of the income statement as filed: the last 3 fiscal years (annual) or 2 quarters (quarterly), latest first.4

Period ending2025-12-312024-12-312023-12-31
Revenue$943.7M$705.1M$787.6M
Cost of sales$15.9M$11.2M$9.1M
Research, development and patent$915.6M$901.5M$899.6M
Selling, general and administrative$393.9M$267.5M$232.6M
Total operating expenses$1.3B$1.2B$1.1B
Loss from operations-$381.7M-$475.1M-$353.7M
Investment income$97.8M$107.0M$89.0M
Interest expense-$17.3M-$17.0M-$12.7M
Interest expense related to sale of future royalties-$73.3M-$73.5M-$68.8M
Gain (loss) on investments, net$10.2M-$2.9M-$1.9M
Other income (expense), net-$15.4M$1.3M$14.1M
Loss before income tax benefit (expense)-$379.6M-$460.1M-$334.0M
Income tax benefit (expense)-$1.8M$6.2M-$32.3M
Net loss-$381.4M-$453.9M-$366.3M
Basic net loss per share (in Dollars per share)-$2.38-$3.04-$2.56
Diluted net loss per share (in Dollars per share)-$2.38-$3.04-$2.56
Shares used in computing basic net loss per share (in Shares)160.0M shares149.5M shares143.2M shares
Shares used in computing diluted net loss per share (in Shares)160.0M shares149.5M shares143.2M shares

Compare IONIS PHARMACEUTICALS INC with another company

Corporate structure

IONIS PHARMACEUTICALS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of IONIS PHARMACEUTICALS INC

  • T. Rowe Price Investment Management, Inc. Filed SCHEDULE 13G/A on IONIS PHARMACEUTICALS INC, latest May 15, 2026 (7 filings since Feb 14, 2023)
  • Capital World Investors Filed SCHEDULE 13G/A on IONIS PHARMACEUTICALS INC, latest May 14, 2026 (3 filings since Feb 13, 2025)
  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on IONIS PHARMACEUTICALS INC, latest Apr 30, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on IONIS PHARMACEUTICALS INC, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
  • Wellington Management Company Filed SCHEDULE 13G/A on IONIS PHARMACEUTICALS INC, latest Aug 12, 2025 (2 filings since Nov 8, 2024)
  • BlackRock Filed SCHEDULE 13G/A on IONIS PHARMACEUTICALS INC, latest Apr 17, 2025 (4 filings since Feb 1, 2022)
  • BB Biotech Filed SC 13G/A on IONIS PHARMACEUTICALS INC, latest Nov 14, 2024 (4 filings since Feb 11, 2022)
  • FMR LLC Filed SC 13G/A on IONIS PHARMACEUTICALS INC, latest Feb 9, 2024 (3 filings since Feb 9, 2022)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on IONIS PHARMACEUTICALS INC, latest Aug 10, 2022 (3 filings since Feb 14, 2022)
  • ARK Investment Management LLC Filed SC 13G on IONIS PHARMACEUTICALS INC, latest Feb 9, 2022
  • IONIS PHARMACEUTICALS INC Carlsbad, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IONIS PHARMACEUTICALS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$109.1M4 Dec 31, 2025$106.3M4 Dec 31, 2024+2.6%
Property and equipment, net$123.0M4 Dec 31, 2025$94.3M4 Dec 31, 2024+30.6%
Operating-lease assets (leased space)$238.5M4 Dec 31, 2025$161.9M4 Dec 31, 2024+47.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$372.3M4 Dec 31, 2025$242.1M4 Dec 31, 2024+53.8%
Marketable securities, current$2.3B4 Dec 31, 2025$2.1B4 Dec 31, 2024+12.1%
Marketable securities, non-current$773.7M4 Dec 31, 2025$652.5M4 Dec 31, 2024+18.6%
Debt securities available for sale$2.4B4 Dec 31, 2025$2.1B4 Dec 31, 2024+14.4%
Equity securities at fair value$55.2M4 Dec 31, 2025$46.3M4 Dec 31, 2024+19.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$10.0M4 Dec 31, 2025$12.5M4 Dec 31, 2024−19.7%
Raw materials$5.6M8 Dec 31, 2024$1.8M8 Dec 31, 2023+207.0%
Work in process$6.7M8 Dec 31, 2024$5.5M8 Dec 31, 2023+21.9%
Finished goods$276.0K8 Dec 31, 2024$154.0K8 Dec 31, 2023+79.2%

Properties, in its own words

As of February 19, 2026, the following are the primary facilities in which we operate:

Owned · Initial Lease · Lease

The rest of Item 2

Property Description · Location · Square Footage · or Leased · Term End Date · Extension Options

Laboratory and office space facility · Carlsbad, CA · 176,300 · Leased · 2037 · Two, five-year options to extend

Laboratory and office space facility · Carlsbad, CA · 164,800 · Leased · 2040 · Two, five-year options to extend

Office and meeting space facility · Carlsbad, CA · 74,000 · Leased · 2037 · Two, five-year options to extend

Manufacturing facility · Carlsbad, CA · 26,800 · Owned

Manufacturing support facility · Carlsbad, CA · 25,800 · Leased · 2031 · None

Office space facility · Boston, MA · 14,300 · Leased · 2038 · None

Office space facility · Carlsbad, CA · 5,800 · Leased · 2027 · None

Warehouse facility · Carlsbad, CA · 4,200 · Leased · 2028 · None

Office space facility · Dublin, Ireland · 3,900 · Leased · 2030 · None

495,900

We believe that our current and future facilities will be adequate for the foreseeable future. Refer to Part IV, Section 15, Note 7, Long-Term Obligations and Commitments, in the Notes to the Consolidated Financial Statements for details on our facilities.

Item 2 of the 10-K filed Feb 26, 2026.3

Leadership

Who has led IONIS PHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stanley T. Crooke2006–2019
  2. Brett P. Monia2020–now

Chair

  1. Stanley T. Crooke2006–2021

President

  1. Stanley T. Crooke2006–2014
  2. Kleanthis G. Xanthopoulos2007

Chief financial officer

  1. Elizabeth L. Hougen2013–now

Chief operating officer

  1. B. Lynne Parshall2008–2018
  2. Stanley T. Crooke2013
  3. Brett P. Monia2018–2019
2010201520202025
Board members and other officers (34)

Former names

  • ISIS PHARMACEUTICALS INCJun 12, 1996 to Dec 18, 20152

Timeline

  1. Sep 23, 20268-K Regulation FD disclosure; Other events51
  2. Sep 4, 20268-K Regulation FD disclosure; Other events52
  3. Sep 4, 20268-K Regulation FD disclosure; Other events53
  4. Jul 29, 20268-K Results of operations54
  5. Jul 10, 20268-K Regulation FD disclosure55
  6. Jul 9, 20268-K Regulation FD disclosure; Other events56
  7. Jun 24, 20268-K Regulation FD disclosure; Other events57
  8. Jun 12, 20268-K Other events58
  9. Jun 8, 20268-K Executive or director change; Shareholder vote; Regulation FD disclosure59
  10. May 28, 20268-K Regulation FD disclosure; Other events60
  11. Apr 29, 20268-K Results of operations61
  12. Apr 21, 20268-K Regulation FD disclosure; Other events62
  13. Jan 3, 2020New chief executive Brett P. Monia becomes CEO12
  14. Jan 4, 2006New chief executive Stanley T. Crooke becomes CEO13

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.80) a share, on Oct 29, 2025.63

When it reported results

  1. Jul 29, 2026Reported quarterly or annual results54
  2. Apr 29, 2026Reported quarterly or annual results61
  3. Feb 25, 2026Reported quarterly or annual results64
  4. Jan 12, 2026Reported quarterly or annual results65
  5. Oct 29, 2025Reported quarterly or annual results66
  6. Jul 30, 2025Reported quarterly or annual results67
  7. Apr 30, 2025Reported quarterly or annual results68
  8. Feb 19, 2025Reported quarterly or annual results69

Drug trials and FDA: coming up

  1. Dec 2026Phase 3 trial readout expected Phase 3 trial of Donidalorsen in Hereditary Angioedema: primary completion expected Dec 2026 (ClinicalTrials.gov NCT05392114).70
  2. Mar 2027Phase 3 trial readout expected Phase 3 trial of Olezarsen in Severe Hypertriglyceridemia: primary completion expected Mar 2027 (ClinicalTrials.gov NCT05681351).71
  3. Apr 2027Phase 1/2 trial readout expected Phase 1/2 trial of ION717 in Prion Disease: primary completion expected Apr 2027 (ClinicalTrials.gov NCT06153966).72
  4. Jun 2027Phase 3 trial readout expected Phase 3 trial of Olezarsen in Familial Chylomicronemia Syndrome: primary completion expected Jun 2027 (ClinicalTrials.gov NCT05185843).73
  5. Aug 2027Phase 3 trial readout expected Phase 3 trial of obudanersen in Angelman Syndrome: primary completion expected Aug 2027 (ClinicalTrials.gov NCT06914609).74
  6. Sep 2027Phase 1/2 trial readout expected Phase 1/2 trial of ION440 in Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome: primary completion expected Sep 2027 (ClinicalTrials.gov NCT06430385).75

Drug trials and FDA: recently

  1. Sep 3, 2026FDA approval FDA approved Zanvastro (zilganersen sodium), a new molecular entity, priority review, orphan drug (NDA 220210).76
  2. Jun 24, 2026FDA approved a new use FDA approved an efficacy supplement for Tryngolza (Autoinjector) (olezarsen sodium), a new use or patient group (NDA 218614, supplement 4).77
  3. Jun 17, 2026Phase 3 trial completed Phase 3 trial of ION363 in Amyotrophic Lateral Sclerosis: primary completion Jun 17, 2026, no results posted yet (ClinicalTrials.gov NCT04768972).78
  4. Mar 25, 2026Phase 3 trial completed Phase 3 trial of Eplontersen in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM): primary completion Mar 25, 2026, no results posted yet (ClinicalTrials.gov NCT04136171).79
  5. Aug 21, 2025FDA approval FDA approved Dawnzera (Autoinjector) (donidalorsen sodium), a new molecular entity, orphan drug (NDA 219407).80
  6. Jan 24, 2025Phase 2 trial completed Phase 2 trial of Donidalorsen in Hereditary Angioedema: primary completion Jan 24, 2025, results posted May 8, 2026 (ClinicalTrials.gov NCT04307381).81
  7. Dec 19, 2024FDA approval FDA approved Tryngolza (Autoinjector) (olezarsen sodium), a new molecular entity, priority review, orphan drug (NDA 218614).82

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

849 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 85 major events, 477 insider forms, 34 large holders, 233 other. The latest 20:

  1. Sep 23, 20268-K CURRENT REPORT FILING EDGAR
  2. Sep 4, 20268-K EDGAR
  3. Sep 4, 20268-K EDGAR
  4. Sep 2, 20264 PRIMARY DOCUMENT EDGAR
  5. Sep 2, 20264 PRIMARY DOCUMENT EDGAR
  6. Sep 2, 20264 PRIMARY DOCUMENT EDGAR
  7. Sep 2, 20264 PRIMARY DOCUMENT EDGAR
  8. Jul 31, 2026S-8 EDGAR
  9. Jul 31, 20264 PRIMARY DOCUMENT EDGAR
  10. Jul 29, 20268-K EDGAR
  11. Jul 29, 202610-Q IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026 EDGAR
  12. Jul 17, 20264 PRIMARY DOCUMENT EDGAR
  13. Jul 17, 20264 PRIMARY DOCUMENT EDGAR
  14. Jul 17, 20264 PRIMARY DOCUMENT EDGAR
  15. Jul 17, 20264 PRIMARY DOCUMENT EDGAR
  16. Jul 10, 20268-K EDGAR
  17. Jul 9, 20268-K EDGAR
  18. Jul 9, 20264 PRIMARY DOCUMENT EDGAR
  19. Jul 9, 20264 PRIMARY DOCUMENT EDGAR
  20. Jul 9, 20264 PRIMARY DOCUMENT EDGAR

The 849 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

256 open-market trades by officers, directors and large owners since October 2021: 4 buys and 252 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 31, 2026Hayden Michael RDirectorBuy5,000$51.60$258.0KForm 4
Jul 30, 2026Hayden Michael RDirectorBuy15,000$53.38$800.7KForm 4
Jul 7, 2026BENNETT C FRANKEVP, Chief Scientific OfficerSale20,536$84.95$1.7MForm 4
Jul 7, 2026Diaz Allene M.DirectorSale10,111$85.42$863.7KForm 4
Jul 7, 2026Kordasiewicz Holly B.EVP, Chief Development OfficerSale362$84.30$30.5KForm 4
Jul 1, 2026KLEIN JOSEPH IIIDirectorSale11,518$79.04$910.4KForm 4
Jun 26, 2026Baroldi JosephEVP, Chief Business OfficerSale5,635$80.16$451.7KForm 4
Jun 26, 2026O'NEIL PATRICK R.EVP CLO & General CounselSale3,069$80.00$245.5KForm 4
Jun 26, 2026Schneider EugeneEVP, Chf Clinical Develop OfcrSale26,000$81.05$2.1MForm 4
Jun 26, 2026Monia Brett PChief Executive OfficerSale50,000$80.59$4.0MForm 4
Jun 25, 2026Monia Brett PChief Executive OfficerSale21,072$78.49$1.7MForm 4
Jun 25, 2026Swayze EricEVP ResearchSale10,602$79.18$839.5KForm 4
Jun 24, 2026Monia Brett PChief Executive OfficerSale14,565$78.41$1.1MForm 4
Jun 15, 2026BERTHELSEN SPENCER RDirectorSale8,000$73.49$587.9KForm 4
Jun 12, 2026Kordasiewicz Holly B.EVP, Chief Development OfficerSale60,846$73.40$4.5MForm 4
Jun 1, 2026BERTHELSEN SPENCER RDirectorSale8,000$75.67$605.4KForm 4
May 14, 2026Monia Brett PChief Executive OfficerSale3,220$78.68$253.3KForm 4
May 13, 2026Monia Brett PChief Executive OfficerSale1,316$78.01$102.7KForm 4
May 4, 2026LOSCALZO JOSEPHDirectorSale77,289$75.06$5.8MForm 4
May 1, 2026KLEIN JOSEPH IIIDirectorSale10,111$73.51$743.2KForm 4

All 256 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Brett P. MoniaChief Executive Officer$1.1M$13.4M93
2025Elizabeth L. HougenEVP, Finance and Chief Financial Officer64$729.8K$4.4M93
2025Richard S. GearyEVP, Chief Development Officer$622.1K$3.3M93
2025Brian BirchlerEVP, Corporate and Development Operations60$580.2K$3.2M93
2025Eric SwayzeEVP, Research$589.0K$3.2M93
2025Patrick R. O’Neil EVPChief Legal Officer and General Counsel$611.8K$3.2M93
2024Brett P. MoniaChief Executive Officer$1.0M$15.4M93
2024Elizabeth L. HougenEVP, Finance and Chief Financial Officer64$700.0K$5.1M93
2024Richard S. GearyEVP, Chief Development Officer$593.9K$3.5M93
2024Patrick R. O’Neil EVPChief Legal Officer and General Counsel$586.9K$3.4M93
2024Eric SwayzeEVP, Research$565.0K$3.4M93
2024Brian BirchlerEVP, Corporate and Development Operations60$531.0K$3.3M93
2023Brett P. MoniaChief Executive Officer$960.9K$12.5M93
2023Elizabeth L. HougenEVP, Finance and Chief Financial Officer64$612.2K$2.9M93
2023Richard S. GearyEVP, Chief Development Officer$569.7K$2.6M93
2023Eric SwayzeEVP, Research$513.8K$2.6M93
2023Patrick R. O’Neil EVPChief Legal Officer and General Counsel$562.9K$2.5M93
2023Brian BirchlerEVP, Corporate and Development Operations60$510.6K$2.4M93

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC24,631,956$2.0B0.1%+75,319
Capital World Investors21,669,226$1.7B0.2%+482,857
BlackRock, Inc.10,704,660$848.8M0.0%+262,184
Vanguard Portfolio Management LLC7,859,529$623.2M0.0%+50,627
Wellington Management Group Llp7,651,415$606.7M0.1%+1,259,599
Vanguard Capital Management LLC7,211,497$571.8M0.0%+93,167
Two Sigma Investments, LP6,252,342$495.7M0.4%+394,713
Royal Bank Of Canada6,182,479$490.2M0.1%+2,380,664
State Street Corp4,334,848$343.7M0.0%+339,284
Geode Capital Management, LLC3,584,024$294.8M0.0%−400,308
Jpmorgan Chase & Co2,671,717$216.2M0.0%+308,150
Artisan Partners Limited Partnership2,640,024$209.3M0.3%+581,716
Tweedy, Browne Co LLC2,280,311$180.8M13.7%+4,686
Deep Track Capital, LP2,200,000$174.4M2.6%+250,000
Goldman Sachs Group Inc2,109,945$167.3M0.0%+410,098
Baker Bros. Advisors LP2,047,727$162.4M0.8%No change
Deerfield Management Company, L.P.1,979,669$157.0M2.0%No change
American Century Companies Inc1,947,076$154.4M0.1%+283,273
Franklin Resources Inc1,623,377$128.7M0.0%+48,354
Charles Schwab Investment Management Inc1,605,054$127.3M0.0%+21,788
Barclays PLC1,603,136$127.1M0.0%+1,313,262
Pictet Asset Management Holding SA1,596,998$127.0M0.1%+162,003
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1,454,672$115.3M0.0%−20,960
Polar Capital Holdings Plc1,454,021$115.3M0.3%+624,510
Alyeska Investment Group, L.P.1,417,916$112.4M0.3%+944,766

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 6, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000+69.1%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How IONIS PHARMACEUTICALS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIONIS PHARMACEUTICALS INC1
  • CIK0000874015
  • Employer ID (EIN)33-03369733
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2855 Gazelle Court, Carlsbad, CA 920101
  • Phone76093192001
  • Shares outstanding166,184,322 as of Jul 23, 202610
  • Public float$5.3B as of Jun 30, 20253
  • AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting3
  • On EDGAR sinceJun 12, 19961
  • Filings2,688 in all: 4 (1,452), 8-K (330), 144 (186), SC 13G/A (118), 10-Q (91), CT ORDER (73), 4/A (38), 3 (33)1
    All 48 form types

    SC 13G (31), DEF 14A (30), 144/A (26), S-8 (26), 10-K (24), 424B2 (23), DEFA14A (21), ARS (19), 8-K/A (18), 424B3 (17), SC 13D/A (13), CORRESP (10), S-3 (10), S-3/A (10), SCHEDULE 13G/A (10), UPLOAD (10), 10-K405 (6), 10-Q/A (6), 5 (6), S-3ASR (6), SC TO-T/A (5), 3/A (4), 424B5 (4), PRE 14A (4), SC 13D (4), SC TO-C (4), 10-K405/A (3), NO ACT (2), POS AM (2), REGDEX (2), SCHEDULE 13G (2), 10-K/A (1), 424B4 (1), 424B7 (1), D (1), EFFECT (1), FWP (1), SC TO-I (1), SC TO-I/A (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Jul 29, 2026
    Proxy statement (DEF 14A) Apr 23, 2026
    Latest 8-K (8-K) Sep 23, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $.001 Par ValueIONSNasdaq

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks IONIS PHARMACEUTICALS INC names in Item 1A of its 10-K filed Feb 26, 2026: 37 risks under these headings, as written.3

  • Risks Related to the Commercialization of our Medicines
  • We have limited experience as a company in commercializing medicines and we will have to continue to invest significant resources to develop our capabilities. If we are unable to effectively establish or maintain an effective commercialization infrastructure, or enter into agreements with third parties to commercialize our medicines, we may not be able to successfully commercialize our medicines.
  • If the market does not accept our medicines, including our commercial medicines and our medicines in development, we are not likely to generate substantial revenues or become consistently profitable.
  • If government or other third-party payers fail to provide adequate coverage and payment rates for our medicines, including our commercial medicines and our medicines in development, or if healthcare reform measures increase our costs, decrease our sales, or negatively impact reimbursement for our products, our revenue will be limited.
  • If we or our partners fail to compete effectively, our medicines, including our commercial medicines and our medicines in development, will not generate significant revenues.
  • Our medicines could be subject to regulatory limitations following approval.
  • We depend on our collaborations with Biogen for the development and commercialization of SPINRAZA and QALSODY.
  • We depend on our collaboration with AstraZeneca for the joint development and commercialization of WAINUA.
  • If we are not successful in expanding our manufacturing capabilities or cannot manufacture our medicines or contract with a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.
  • Risks Related to the Development and Regulatory Approval of our Medicines
  • If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for our commercial medicines, we or our partners cannot sell them in the applicable markets.
  • If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to abandon one or more of our drug development programs.
The other 27 risks
  • Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in late-stage clinical studies. Similarly, topline, preliminary or interim data we release for any of our clinical studies may not be indicative of full or final results from such study.
  • We depend on third parties to conduct clinical studies for our medicines and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.
  • Since corporate partnering is part of our strategy to fund the advancement and commercialization of some of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on those drug development programs.
  • Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development and commercial programs.
  • We may not be able to benefit from designations for our medicines from regulatory authorities that are intended to confer benefits such as financial incentives or an accelerated regulatory pathway.
  • Risks Associated with our Businesses as a Whole
  • Risks related to our financial condition
  • If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.
  • We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.
  • We may not be entitled to obtain additional milestone payments under our royalty monetization agreement with Royalty Pharma.
  • Risks related to our intellectual property
  • If we cannot protect our patent rights or our other proprietary rights, others may compete more effectively against us.
  • Intellectual property litigation could be expensive and prevent us from pursuing our programs.
  • Risks related to product liability
  • We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.
  • Risks related to our personnel
  • The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.
  • Risks related to health epidemics, climate change and other events
  • Our business may be adversely affected by health epidemics, climate change, extreme weather events, fires, earthquakes, war, civil or political unrest, terrorism or disruptions of the U.S. government.
  • Risks related to personal information, cybersecurity, social media and artificial intelligence
  • We are dependent on data as well as information technology systems and infrastructure, which exposes us to data protection risks.
  • The increasing use of social media platforms presents new risks and challenges.
  • We use artificial intelligence in certain aspects of our business, and challenges with properly managing its use could adversely affect our business.
  • Risks related to our securities and the global credit markets
  • If we do not progress in our programs as anticipated, the price of our securities could decrease.
  • If the price of our securities continues to be highly volatile, this could make it harder to liquidate your investment and could increase your risk of suffering a loss.
  • Negative conditions in the global credit markets and financial services and other industries may adversely affect our business, financial condition or stock price.
  • Provisions in our certificate of incorporation, bylaws, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.
  • Future sales of our common stock in the public market could adversely affect the trading price of our securities.
  • Risks related to compliance with laws
  • Our operations are subject to extensive legal and regulatory requirements affecting the health care industry.
  • Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
  • Risks related to taxes
  • Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.
  • Our future taxable income could be impacted by changes in tax laws, regulations and treaties.
  • We could be subject to additional tax liabilities.

Legal proceedings

For details of legal proceedings, refer to Part IV, Item 15, Note 11, Legal Proceedings, in the Notes to the Consolidated Financial Statements.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93